INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Michigan–Ann Arbor
Ann Arbor, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Michigan–Ann Arbor (51)
2023
-
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
International Journal of Molecular Sciences, Vol. 24, Núm. 20
-
Emerging mechanistic insights of selective autophagy in hepatic diseases
Frontiers in Pharmacology, Vol. 14
-
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020
2022
-
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865
-
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 2, pp. 422-432
-
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950
-
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6
-
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1
-
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024
-
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1953-1963
-
Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1986-1998.e2
2021
-
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144
-
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
Journal of Allergy and Clinical Immunology
-
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 11, pp. 3918-3928
-
Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19
New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802
-
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
HemaSphere, Vol. 5, Núm. 11, pp. E646
2020
-
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Blood, Vol. 136, Núm. 21, pp. 2401-2409
-
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Theranostics, Vol. 10, Núm. 23, pp. 10743-10768